Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 4:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: "mild cognitive impairment" Condition: Alzheimer's Disease Clear all
Completed No phase listed Observational Accepts healthy volunteers

Cognitive Screening Made Easy for PCPs

NCT05082883
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Cognitive Decline
Interventions
Risk Assessment Cognitive Screening
Diagnostic Test
Lead sponsor
University of Texas at Austin
Other
Eligibility
60 Years and older
Enrollment
152 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 30, 2023 · Synced Oct 14, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 Study of BIIB092 in Participants With Early Alzheimer's Disease

NCT03352557
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
BIIB092, Placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
50 Years to 80 Years
Enrollment
654 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
52
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2022 · Synced Oct 14, 2026, 4:06 AM EDT
Active, not recruiting Not applicable Interventional

Sleep Disturbance and Emotion Regulation Brain Dysfunction as Mechanisms of Neuropsychiatric Symptoms in Alzheimer's Dementia

NCT04100057
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Neuropsychiatric Symptoms, Sleep Disturbance
Interventions
Cognitive Behavioral Therapy for Insomnia (CBT-I), Desensitization Therapy for insomnia (DT-I)
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
50 Years to 90 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Results available

Tau Imaging in Professional Fighters

NCT02278354
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Flortaucipir F18, Brain PET scan
Drug · Procedure
Lead sponsor
Avid Radiopharmaceuticals
Industry
Eligibility
18 Years and older · Male only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Sep 10, 2020 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

NCT02006641
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Placebo, Idalopirdine
Drug
Lead sponsor
H. Lundbeck A/S
Industry
Eligibility
50 Years and older
Enrollment
858 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
48
States / cities
Phoenix, Arizona • Fayetteville, Arkansas • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2018 · Synced Oct 14, 2026, 4:06 AM EDT
Recruiting Not applicable Interventional

Reducing African American's Alzheimer's Risk Through Exercise-Mild Cognitive Impairment (RAATE-MCI)

NCT04956549
View directory record Official record
Conditions
Dementia of Alzheimer Type
Interventions
Physical activity program, Successful Aging
Behavioral
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
60 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 17, 2025 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 4 Interventional Results available

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

NCT03811847
View directory record Official record
Conditions
Alzheimer Dementia
Interventions
Methylphenidate Extended Release Oral Capsule, Placebo
Drug · Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
55 Years to 95 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 1 Interventional Results available

Open Label Extension Study Evaluating Safety and Tolerability of AAB-003 (PF-05236812) in Subject With Mild to Moderate Alzheimer's Disease

NCT01369225
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
AAB-003 (PF-05236812)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
50 Years to 90 Years
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Hallandale, Florida • Ocala, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2017 · Synced Oct 14, 2026, 4:06 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Amyloid Prediction in Early Stage Alzheimer's Disease Through Speech Phenotyping

NCT04928976
View directory record Official record
Conditions
Alzheimer Disease, Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease, Alzheimer's Disease (Incl Subtypes), Mild Cognitive Impairment
Interventions
Not listed
Lead sponsor
Novoic Limited
Industry
Eligibility
50 Years to 85 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Ana, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2021 · Synced Oct 14, 2026, 4:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Semorinemab in Patients With Prodromal to Mild Alzheimer's Disease

NCT03289143
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Semorinemab, Placebo, [18F]GTP1
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
457 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
43
States / cities
Birmingham, Alabama • Glendale, California • Irvine, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 14, 2026, 4:06 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

NCT04505735
View directory record Official record
Conditions
Alzheimer Disease, Healthy Aging
Interventions
11C-PiB
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 3 Interventional Results available

Renew NCP-5 for the Treatment of Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild Dementia of the Alzheimer's Type

NCT03721705
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Cognitive Impairment, Mild Dementia, Cognitive Decline, Dementia, Alzheimer Type
Interventions
Renew NCP-5
Device
Lead sponsor
Renew Research, LLC
Other
Eligibility
55 Years to 85 Years
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Irvine, California • Lady Lake, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Optimization of Blood Levels of 25(OH)-Vitamin D in African Americans

NCT04939792
View directory record Official record
Conditions
Vitamin D Deficiency
Interventions
Vitamin D, Placebo, Vitamin D + L-cysteine, L-cysteine
Drug
Lead sponsor
Louisiana State University Health Sciences Center Shreveport
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Shreveport, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 8, 2023 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Not applicable Interventional Results available

Risk Evaluation and Education for Alzheimer's Disease (REVEAL) IV

NCT01434667
View directory record Official record
Conditions
Mild Cognitive Impairment
Interventions
APOE genotype and Alzheimer's disease risk disclosure, Alzheimer's disease risk disclosure
Behavioral
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
146 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
3
States / cities
Washington D.C., District of Columbia • Ann Arbor, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 14, 2026, 4:06 AM EDT
Terminated Not applicable Interventional Results available

Brain Energy Metabolism and Sleep in Adults

NCT03929302
View directory record Official record
Conditions
Alzheimer Disease, Mild Cognitive Impairment, Cognitive Change, Energy Metabolism, Sleep Disturbance
Interventions
MyTAP oral appliance plus mouth shield
Device
Lead sponsor
The University of Texas at Dallas
Other
Eligibility
55 Years to 85 Years
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2024 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Advance Care Planning in Cognitive Disorders Clinic

NCT03864965
View directory record Official record
Conditions
Advance Care Planning
Interventions
Advance Care Planning
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 100 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 14, 2026, 4:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Predictors of Cognitive Decline in Normal Aging

NCT00094939
View directory record Official record
Conditions
Alzheimer Disease, Dementia
Interventions
Not listed
Lead sponsor
National Institute on Aging (NIA)
NIH
Eligibility
60 Years to 80 Years
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 14, 2009 · Synced Oct 14, 2026, 4:06 AM EDT
Terminated Phase 4 Interventional Results available

Modafinil Treatment for Sleep/Wake Disturbances in Older Adults

NCT00626210
View directory record Official record
Conditions
Insomnia, Sleep Initiation and Maintenance Disorders, Alzheimer Disease
Interventions
modafinil
Drug
Lead sponsor
VA Palo Alto Health Care System
Federal
Eligibility
50 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2019 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Tolerability of SAGE-718 in Participants With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (AD)

NCT04602624
View directory record Official record
Conditions
Alzheimer Disease, Cognitive Dysfunction, Mild Dementia
Interventions
SAGE-718
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
50 Years to 80 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
10
States / cities
Phoenix, Arizona • Redlands, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2025 · Synced Oct 14, 2026, 4:06 AM EDT
Enrolling by invitation No phase listed Observational

Georgia Memory Net Anti-Amyloid Monoclonal Antibody Registry

NCT05999084
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Anti-amyloid Monoclonal Antibodies (mAbs), Standard of Care
Drug · Combination Product
Lead sponsor
Emory University
Other
Eligibility
50 Years to 90 Years
Enrollment
735 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Albany, Georgia • Atlanta, Georgia • Augusta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Phase 2 Interventional Results available

Simufilam (PTI-125), 100 mg, for Mild-to-moderate Alzheimer's Disease Patients

NCT04388254
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Simufilam 100 mg oral tablet, Placebo
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
50 Years to 85 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
15
States / cities
Gilbert, Arizona • Surprise, Arizona • Imperial, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2025 · Synced Oct 14, 2026, 4:06 AM EDT
Active, not recruiting Phase 3 Interventional

A Donanemab (LY3002813) Study in Participants With Preclinical Alzheimer's Disease (TRAILBLAZER-ALZ 3)

NCT05026866
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Donanemab, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
55 Years to 80 Years
Enrollment
2,996 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
198
States / cities
Birmingham, Alabama • Homewood, Alabama • Huntsville, Alabama + 163 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced Oct 14, 2026, 4:06 AM EDT
Completed Not applicable Interventional

Improving Everyday Task Performance Through Repeated Practice in Virtual Reality.

NCT04315337
View directory record Official record
Conditions
Alzheimer Disease, Mild Dementia, Mild Cognitive Impairment, Dementia, Dementia, Vascular, Dementia Alzheimers, Dementia, Mild, Dementia, Mixed, Dementia of Alzheimer Type
Interventions
Virtual Kitchen Training
Behavioral
Lead sponsor
Temple University
Other
Eligibility
65 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 14, 2026, 4:06 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A SMART Trial of Adaptive Exercises to Optimize Aerobic-Fitness Responses

NCT05877196
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer Disease, Cognitive Impairment, Cognitive Decline, Memory Loss, Memory Impairment
Interventions
Moderate Intensity Continuous Training (MICT), Chair-based Stretch, High-Intensity Interval Training (HIIT), Combined Aerobic Resistance Exercise (CARE)
Behavioral
Lead sponsor
Arizona State University
Other
Eligibility
65 Years and older
Enrollment
216 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2028
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 14, 2026, 4:06 AM EDT